Recent clinical data demonstrates that subcutaneous mosunetuzumab provides a highly effective and safer alternative to the traditional intravenous formulation for patients with relapsed or refractory follicular lymphoma. This pivotal phase 2 analysis evaluated the pharmacokinetics, efficacy, and safety of the subcutaneous (SC) route. Researchers found that SC administration significantly improves patient convenience while maintaining therapeutic levels. Consequently, this development marks a significant shift toward outpatient-friendly immunotherapy for hematological malignancies.

Primary Outcomes and Pharmacokinetics

The study evaluated 94 patients receiving the SC formulation against a comparator cohort of 90 patients treated intravenously. Importantly, the study successfully met its co-primary pharmacokinetic endpoints. The results showed non-inferior exposure of the drug when clinicians administered it subcutaneously compared to the intravenous route. Specifically, the geometric mean ratio for the area under the curve remained consistent across both groups. Therefore, clinicians can expect similar drug performance regardless of the delivery method.

Efficacy of Subcutaneous Mosunetuzumab

Regarding clinical performance, the efficacy of subcutaneous mosunetuzumab mirrors that of the intravenous version. The overall response rate reached 76.6%, while the complete response rate stood at 61.7%. Moreover, the median duration of complete response extended to an impressive 34.6 months. These findings indicate that the SC formulation offers durable disease control for patients who failed two or more prior lines of therapy. Furthermore, the progression-free survival reached a median of 23.7 months, confirming its long-term clinical viability.

Safety Profile and Reduced Cytokine Release Syndrome

A major highlight of this study involves the improved safety profile of the SC injection. Cytokine release syndrome (CRS) occurs frequently with bispecific antibodies. However, the SC group experienced a numerically lower rate of CRS at 29.8% compared to 44.4% in the IV group. Additionally, the severity of these events was significantly lower, with fewer grade 2 or higher cases reported. This reduction in toxicity allows for safer administration and better patient tolerance. Consequently, these improvements may facilitate broader use in community-based oncology settings.

Frequently Asked Questions

How is subcutaneous mosunetuzumab administered?

Subcutaneous mosunetuzumab is given as a fixed-duration treatment. The dosing schedule involves step-up doses during the first cycle (5 mg on Day 1, followed by 45 mg on Days 8 and 15) and then 45 mg doses in subsequent cycles.

What are the primary benefits of the SC formulation over IV?

The SC formulation offers shorter administration times, lower rates of cytokine release syndrome, and increased accessibility for outpatient treatment. These factors contribute to clinically meaningful improvements in patient safety and convenience.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals should perform their own independent evaluation. Refer to the latest local and national guidelines for clinical practice.

References

Bartlett NL et al. Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis. Am J Hematol. 2026 Mar 20. doi: 10.1002/ajh.70225. PMID: 41862428.

ClinicalTrials.gov. A Study Evaluating the Safety and Efficacy of Mosunetuzumab in Patients With B-Cell Non-Hodgkin Lymphoma. NCT02500407.

Budde LE et al. Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. N Engl J Med. 2022;387(24):2211-2222.